Skip to main content

HCA COVID-19 Activities: Monitoring of Critical Drugs and Assessment of Natural History of Disease

Basic Details
Date Posted
Status
In progress
Description

This activity encompasses two aims that are using inpatient electronic health record data from HCA Healthcare:

Aim 1: The objective for Aim 1 is to describe the natural history of disease among hospitalized COVID-19 patients as identified based on diagnosis codes and/or laboratory results. This project will describe patients’ clinical characteristics, healthcare utilization, disease progression, and outcomes. Queries will be updated periodically to understand trends in the disease course and patient care over time.
 

Aim 2: The objective for Aim 2 is to establish the capacity to monitor critical drugs used in the care of hospitalized COVID-19 patients, and to sequentially monitor utilization through repeated data updates.
 

These projects build on the work conducted for the FDA’s Office of Counterterrorism and Emerging Threats (OCET) in understanding how the Sentinel System may be useful to study the safety and effectiveness of medical countermeasures.

Information
Time Period
January 2019 - Current
Population / Cohort
All individuals
Data Source(s)
HCA Healthcare
Related Links
Related Link(s)
FDA Sentinel System's Coronavirus (COVID-19) Activities
Sentinel Methods Project: Assessing Sentinel System Capability to Collect and Analyze Medical Countermeasure Data for the FDA Office of Counterterrorism and Emerging Threats (OCET)
Presentation: High Dose Dexamethasone for COVID-19 Not Common in a Large US Hospital Network
Publication: Treatment and Care Received by Children Hospitalized with COVID-19 in a Large Hospital Network in the United States, February 2020 to September 2021
Publication: Validity of Inpatient Electronic Health Record-Based Measures of Oxygen-Related Therapy in the United States: Lessons Applicable for Studying COVID-19 Endpoints
Publication: Dexamethasone Dose for COVID-19 in a Large U.S. Hospital Network From April 2020 to May 2023
Workgroup Leader(s)

Sarah Dutcher, PhD; Grace Chai, PharmD; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

Candace Fuller, PhD, MPH; Sruthi Adimadhyam, PhD, MS; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

Workgroup Member(s)

Michael Nguyen, MD; Robert Ball, MD, MPH, ScM; Brian Kit, MD, MPH; Catherine Corey, MSPH; Corinne Woods, RPh, MPH; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

Noelle Cocoros, DSc, MPH; Katie Haffenreffer; Austin Cosgrove; Soowoo Back, MPH; Casie Horgan, MPH; Jennifer Noble; Neha Varma, MPH; Abinav Gowda; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA